Increased ischemic stroke, acute coronary artery disease and mortality in patients with granulomatosis with polyangiitis and microscopic polyangiitis.

OBJECTIVE The aim of our study was to assess major cardiovascular event incidence, predictors, and mortality in ANCA-associated vasculitis (AAV). METHODS We conducted a retrospective cohort study of all GPA or MPA, according to Chapel Hill Consensus Conference classification criteria, diagnosed between 1981 and 2015. Major cardiovascular event was defined as acute coronary artery disease, or ischemic stroke, or peripheral vascular disease requiring a revascularization procedure. We calculated the comparative morbidity/mortality figure (CMF) and we used Cox proportional hazards regression models to assess the risk of coronary artery disease, ischemic stroke associated with AAV, after adjusting for covariates. RESULTS 125 patients, 99 GPA (79,2%) and 26 MPA (20,8%), were followed 88.4 ± 78.3 months. Ischemic stroke incidence was four times higher than in the general population (CMF 4,65; 95% CI 4,06-5,31). Coronary artery disease incidence was four times higher than in the general population (CMF 4,22; 95% CI 1,52-11,68). Smoking habits and history of coronary artery disease were strongly associated with coronary artery disease occurrence (adjusted HR 8.8; 95% CI 2.12-36.56, and adjusted HR 10.3; 95% CI 1.02-104.5, respectively). ENT flare-up was an independent protective factor for coronary artery disease occurrence. We did not identify factors significantly associated with stroke occurrence. The age-adjusted mortality rate was 22.5 per 1000 person-years. Mortality in AAV was 1.5 times higher than in the general population (CMF 1.56; 95% CI 1.34-1.83). CONCLUSION AAV have a significantly increased risk of mortality, ischemic stroke, and coronary artery disease.

[1]  S. Renaud,et al.  Wine, alcohol, platelets, and the French paradox for coronary heart disease , 1992, The Lancet.

[2]  F. Moosig,et al.  Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. , 2016, Rheumatology.

[3]  B. Baslund,et al.  Impact of pre-existing co-morbidities on mortality in granulomatosis with polyangiitis: a cohort study. , 2016, Rheumatology.

[4]  R. Moots,et al.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.

[5]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[6]  M. Roman,et al.  Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. , 2008, The American journal of medicine.

[7]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[8]  L. Mouthon,et al.  [Pathophysiology of ANCA-associated vasculitides]. , 2012, Presse medicale.

[9]  Nancy M Albert,et al.  Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[10]  P. Heeringa,et al.  Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic? , 2003, The Netherlands journal of medicine.

[11]  A. Simon,et al.  Atherosclerosis in ANCA‐Associated Vasculitides , 2007, Annals of the New York Academy of Sciences.

[12]  C. Cooper,et al.  Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study , 2004, Heart.

[13]  R. D'Agostino,et al.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.

[14]  Richard A Watts,et al.  The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK Clinical Practice Research Datalink , 2016, Rheumatology.

[15]  D. Arveiler,et al.  Gender- and age-specific trends in coronary heart disease mortality in France from 2000 to 2007: results from the MONICA registers , 2014, European journal of preventive cardiology.

[16]  Mahboob Rahman,et al.  The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. , 2008, The American journal of cardiology.

[17]  Hyon K. Choi,et al.  Risk of Myocardial Infarction and Stroke in Patients With Granulomatosis With Polyangiitis (Wegener's): A Population‐Based Study , 2016, Arthritis & rheumatology.

[18]  P. Merkel,et al.  A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis , 2011, Arthritis care & research.

[19]  P. Merkel,et al.  Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). , 2005, Arthritis and rheumatism.

[20]  G L Freeman,et al.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. , 2001, Arthritis and rheumatism.

[21]  T. MacDonald,et al.  Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease , 2004, Annals of Internal Medicine.

[22]  J. Stone,et al.  Nationwide Trends in Hospitalizations and In‐Hospital Mortality in Granulomatosis With Polyangiitis (Wegener's) , 2016, Arthritis care & research.

[23]  P. Ravaud,et al.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.

[24]  M. Ward.  Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[25]  A. Smit,et al.  Accelerated atherosclerosis in patients with Wegener’s granulomatosis , 2004, Annals of the rheumatic diseases.

[26]  L. Rabbani,et al.  Evidence for C-Reactive Protein's Role in (CRP) Vascular Disease: Atherothrombosis, Immuno-Regulation and CRP , 2004, Journal of Thrombosis and Thrombolysis.

[27]  J. Ruidavets,et al.  Incidence, recurrence, and case fatality rates for myocardial infarction in southwestern France, 1985 to 1993 , 2000, Heart.

[28]  D. Brotman,et al.  Does altered glucocorticoid homeostasis increase cardiovascular risk? , 2004, Cardiovascular research.

[29]  R. Moots,et al.  Corticosteroids: do they damage the cardiovascular system? , 1994, Postgraduate medical journal.

[30]  P. Nightingale,et al.  Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis , 2009, Annals of the rheumatic diseases.

[31]  JoAnn E. Manson,et al.  Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis , 2003, Circulation.

[32]  P. Höglund,et al.  Long-term patient survival in ANCA-associated vasculitis , 2010, Annals of the rheumatic diseases.

[33]  A. Tedgui,et al.  IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[34]  A. Simon,et al.  Increased prevalence of subclinical atherosclerosis in patients with small-vessel vasculitis , 2006, Heart.

[35]  S. Heymans,et al.  Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. , 2015, International journal of cardiology.

[36]  W. Koldingsnes,et al.  Predictors of survival and organ damage in Wegener's granulomatosis. , 2002, Rheumatology.

[37]  L. Mouthon,et al.  The Five-Factor Score Revisited: Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort , 2011, Medicine.

[38]  J. Townend,et al.  Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa , 2003, Annals of the rheumatic diseases.

[39]  B. Baslund,et al.  High Risk of Pulmonary Embolism and Deep Venous Thrombosis but Not of Stroke in Granulomatosis With Polyangiitis (Wegener's) , 2014, Arthritis care & research.

[40]  M. Heller,et al.  Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. , 2011, Arthritis and rheumatism.

[41]  Y. Béjot,et al.  Stroke associated with giant cell arteritis: a population-based study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[42]  M. Boers,et al.  Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies , 2018, Rheumatology.

[43]  L. Dreyer,et al.  Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. , 2009, Arthritis and rheumatism.

[44]  L. Mouthon,et al.  Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. , 2004, Arthritis and rheumatism.

[45]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[46]  Khusru Asadullah,et al.  Mechanisms involved in the side effects of glucocorticoids. , 2002, Pharmacology & therapeutics.

[47]  H. Raspe,et al.  Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force , 2007, Annals of the rheumatic diseases.

[48]  C. Ferro,et al.  Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. , 2009, Arthritis and rheumatism.

[49]  D. Arveiler,et al.  Impact of cardiovascular risk factor control on long-term cardiovascular and all-cause mortality in the general population , 2016, Annals of medicine.

[50]  L. Mouthon,et al.  Factors Associated with Major Cardiovascular Events in Patients with Systemic Necrotizing Vasculitides: Results of a Longterm Followup Study , 2014, The Journal of Rheumatology.